Effect of Gemcitabine-associated Thrombocytopenia on the Survival Time of Patients with Advanced Non-small Cell Lung Cancer
10.3969/j.issn.1008-049X.2018.03.013
- VernacularTitle:吉西他滨相关血小板减少对晚期非小细胞肺癌患者生存时间的影响
- Author:
Fei ZHU
1
;
Yufeng WEI
;
Zeng WANG
;
Jiawen YU
;
Fangjun CHEN
;
Yun SHAO
;
Wanzhu ZHANG
Author Information
1. 舟山市妇幼保健院 浙江舟山316000
- Keywords:
Gemcitabine;
Thrombocytopenia;
Non-small cell lung cancer;
Survival time
- From:
China Pharmacist
2018;21(3):429-431
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effect of gemcitabine-associated thrombocytopenia on the survival time of patients with ad-vanced non-small cell lung cancer (NSCLC).Methods: The data of patients with advanced non-small cell lung cancer treated with gemcitabine from January to December 2011 were retrospectively collected. According to the lowest platelet (PLT) value of the first treatment of gemcitabine,the patients were divided into two groups,PLT higher than 50 × 109·L-1group(43 cases) and PLT lower than 50 × 109·L-1group(24 cases). The survival time was retrieved by referring to the electronic medical records. The relevant in-dices in the two groups were compared and analyzed by COX multiple factors. Results:A total of 67 patients were enrolled in the stud-y. Except for the pathological type,there were no significant differences in gender,age and chemotherapy cycle between the groups(P>0.05). There was significant difference in the survival time between the groups (P<0.05). The median survival time of the pa-tients with PLT higher than 50 × 109·L-1was significantly longer than that of the patients with PLT less than 50 × 109·L-1. Con-clusion:Compared with the patients with mild thrombocytopenia(I/II),gemcitabine induced severe thrombocytopenia(III/IV) in the patients with advanced non-small cell lung cancer(NSCLC) has effect on the survival time of the patients. Therefore,it is necessary to do a good job in the prevention and treatment of thrombocytopenia.
